Regentis Biomaterials Ltd. (NYSE American: RGNT) is advancing its regenerative cartilage repair technology, GelrinC, a cell-free, off-the-shelf degradable hydrogel implant designed to support knee cartilage regeneration. The implant gradually resorbs over six to nine months as new tissue fills the treated area, offering a potential alternative to traditional treatments like microfracture. According to the company, its Pilot/Phase II study showed 100% greater pain improvement compared with microfracture, and 24-month follow-up results showed a mean MOCART score of 88.8 out of 100, an MRI-based measure of cartilage repair quality. These outcomes are detailed in a recent article featured on Regentis Biomaterials (NYSE American: RGNT).
The significance of these findings lies in the growing emphasis on durable, long-term treatment outcomes in orthopedic medicine. GelrinC has already received a CE mark in Europe, providing a commercialization pathway in that market, while Regentis advances its pivotal Phase III clinical study in the United States and prepares for the FDA's Premarket Approval process. The company is also working to complete enrollment in its U.S. study and expand commercialization efforts. With approximately 470,000 cartilage knee repair cases annually in the U.S. and no off-the-shelf treatment currently available, GelrinC could address a substantial unmet need if approved. For a deeper look, the full article is available at https://ibn.fm/cTSlo.
The announcement was disseminated through BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions via InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and corporate communications solutions. The latest news and updates relating to RGNT are available in the company's newsroom at https//ibn.fm/RGNT. This content has been disseminated on behalf of Regentis Biomaterials Ltd. as part of a paid investor awareness and marketing engagement.
